The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.
The study has also laid the groundwork for similar efforts in other crops, leading to a newly developed high-oleic safflower oil.
The company also disclosed that it intends to continue working on its non-HBV RNAi drugs that have entered human testing, but was less clear about earlier-stage ones.
The news marks a key milestone for Tekmira, which announced earlier this month that it would merge with OnCore Biopharma to become an HBV-focused drug developer.
The company is also pushing ahead with a microRNA-replacement therapy that is designed to improve patient response to colon cancer treatment.
The news marks the latest setback for the company, which came under fire late last year over disappointing clinical results on the drug.
Following the transaction, hepatitis B will become Tekmira's top priority, although the company said it will continue work on its other RNAi programs.
The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.
The program is part of the company's BioDirect initiative, which relates to the use of topically applied RNAi-based treatments for pest, weed, and disease control in crop plants.
The RNAi-based drug is designed to specifically target the strain of the virus responsible for the current outbreak.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.